PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company specializing in innovative treatments for unmet needs in neurodevelopmental disorders, has recently introduced a groundbreaking regulatory strategy that could potentially pave the way for the approval of its lead product candidate, Suramin, in the United States. During a recent episode of the Bell2Bell (“B2B”) Podcast, Chairman and CEO Howard Weisman, along with Buzz Woods from Corporate Communications, delved into this strategy.
To hear the interview, please visit https://ibn.fm/4yGe6.
Suramin, a longstanding treatment for early-stage East African sleeping sickness (Human African Trypanosomiasis or “HAT”), has yet to receive approval for use in the United States for any indication, a gap that PaxMedica aims to bridge. Weisman underscored the crucial link between their regulatory approach for HAT and their overarching mission of addressing Autism Spectrum Disorder (“ASD”), with a specific emphasis on the role of the Investigational New Drug application (“IND”) in facilitating a large-scale study in ASD.
As PaxMedica continues to navigate the complex regulatory landscape, the company remains resolute in its commitment to drive pioneering advancements in neurology and biopharmaceutical research, particularly directed towards addressing the pressing unmet needs in the treatment of neurodevelopmental disorders.
To hear the interview, please visit https://ibn.fm/4yGe6.
For more information, visit the company’s website at www.PaxMedica.com.
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
Immunotherapy has emerged as a key weapon in the fight against cancer. However, nearly 80% of patients either don’t respond to…
Cardiovascular disease remains the leading cause of death in the United States. One of the most persistent…
The scale and consequences of cardiovascular disease reinforce why innovation in this space remains essential.…
New research has mapped how breast tissues change as women age. The findings help to explain why breast…
During a recent House hearing conducted by the Ways and Means Committee, hospital CEOs were put on the…
Most cancer patients report cognitive deterioration, such as memory loss and difficulty concentrating as they…